GT Biopharma Inc (GTBP): 1615EpCAM133 TetraKE for solid tumor...

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

GT Biopharma Inc (GTBP)

Reply Private New

Keep Last Read

Next 10 Prev Next

Send PM Follow Ignore

Followers	0
Posts	43
Boards Moderated	0
Alias Born	07/02/2017

Re: None

Sunday, 07/23/2017 10:24:06 PM

Sunday, July 23, 2017 10:24:06 PM

1615EpCAM133

TetraKE for solid tumors, which will enter the clinic after the TriKE molecule CD16/IL-15/CD33.

Again like the TriKE molecule for liquid tumors (targeting mainly AML). TetraKE looks to be a promising molecule for solid tumors (mainly for prostate, breast, and potentially colon cancer) this is because of the modified IL-15 crosslinker, which allows for NK cell proliferation.

The most promising piece of information about TriKEs and TetraKEs is that it targets carcinoma cells rather than any specific type of cancer cells. Meaning it has the TriKE platform can be used on a myriad of cancers subtypes.

For the previous post in regards to who will be the next CMO again, my guess is still Mace Rothenberg.

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent GTBP News

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:46:25 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 05:15:12 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 08:30:39 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 10:00:11 PM
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/06/2023 10:25:12 PM
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/06/2023 10:23:32 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/06/2023 10:21:33 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/01/2023 01:00:37 PM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/27/2023 09:23:48 PM
Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 09/19/2023 03:56:06 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/22/2023 08:55:28 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2023 11:29:58 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2023 11:26:31 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2023 01:30:27 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/05/2023 01:00:11 PM

More GTBP News

InvestorsHub NewsWire

FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM

Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow